These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

217 related items for PubMed ID: 5936445

  • 1. Chemotherapy of leukemia L1210 in mice with 1-beta-d-arabinofuranosylcytosine hydrochloride. I. Influence of treatment schedules.
    Kline I, Venditti JM, Tyrer DD, Goldin A.
    Cancer Res; 1966 May; 26(5):853-9. PubMed ID: 5936445
    [No Abstract] [Full Text] [Related]

  • 2. N4-Behenoyl-1-beta-D-arabinofuranosylcytosine as a potential new antitumor agent.
    Aoshima M, Tsukagoshi S, Sakurai Y, Oh-ishi JI, Ishida T.
    Cancer Res; 1977 Aug; 37(8 Pt 1):2481-6. PubMed ID: 872077
    [Abstract] [Full Text] [Related]

  • 3. Separate and sequential chemotherapy of mouse leukemia L1210 with 1-beta-D-arabinofuranosylcytosine hydrochloride and 1,3-bis(2-chloroethyl)-1-nitrosourea.
    Tyrer DD, Kline I, Venditti JM, Goldin A.
    Cancer Res; 1967 May; 27(5):873-9. PubMed ID: 6025252
    [No Abstract] [Full Text] [Related]

  • 4. Evaluation of antileukemic agents in advanced leukemia L1210 in mice. X.
    Kline I, Gang M, Tyrer DD, Venditti JM, Artis EW, Goldin A.
    Cancer Chemother Rep 2; 1972 Nov; 3(1):1-69. PubMed ID: 4660732
    [No Abstract] [Full Text] [Related]

  • 5. Circadian optimization of the treatment of L1210 leukemia with 1-beta-D-arabinofuranosylcytosine, cyclophosphamide, vincristine and methylprednisolone.
    Burns ER, Scheving LE.
    Chronobiologia; 1980 Nov; 7(1):41-51. PubMed ID: 7438892
    [No Abstract] [Full Text] [Related]

  • 6. Enhancement by tetrahydrouridine of 1-beta-D-arabinofuranosylcytosine (cytarabine) oral activity in L1210 leukemic mice.
    Neil GL, Moxley TE, Manak RC.
    Cancer Res; 1970 Aug; 30(8):2166-72. PubMed ID: 4990003
    [No Abstract] [Full Text] [Related]

  • 7. Electronic volume analysis of L1210 chemotherapy.
    Zucker RM, Helfman D.
    Cancer Res; 1976 Dec; 36(12):4434-8. PubMed ID: 1000492
    [Abstract] [Full Text] [Related]

  • 8. Role of liposome type and route of administration in the antitumor activity of liposome-entrapped 1-beta-D-arabinofuranosylcytosine against mouse L1210 leukemia.
    Rustum YM, Dave C, Mayhew E, Papahadjopoulos D.
    Cancer Res; 1979 Apr; 39(4):1390-5. PubMed ID: 421223
    [No Abstract] [Full Text] [Related]

  • 9. Evaluation of antileukemic agents in advanced leukemia L1210 in mice. IX.
    Kline I, Gang M, Tyrer DD, Venditti JM, Artis EW, Goldin A.
    Cancer Chemother Rep 2; 1971 Apr; 2(1):65-133. PubMed ID: 5565539
    [No Abstract] [Full Text] [Related]

  • 10. Chemotherapy of leukemia L1210 in mice with 1-beta-D-arabinofuranosylcytosine hydrochloride. II. Effectiveness against intracerebrally and subcutaneously inoculated leukemic cells.
    Kline I, Venditti JM, Tyrer DD, Mantel N, Goldin A.
    Cancer Res; 1966 Sep; 26(9):1930-7. PubMed ID: 5924958
    [No Abstract] [Full Text] [Related]

  • 11. Therapy of central nervous system leukemia in mice by liposome-entrapped 1-beta-D-arabinofuranosylcytosine.
    Hong F, Mayhew E.
    Cancer Res; 1989 Sep 15; 49(18):5097-102. PubMed ID: 2766280
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Effects of 2'-deoxycoformycin, 9-beta-D-arabinofuranosyladenine 5'-phosphate, and 1-beta-D-arabinofuranosylcytosine triple combination therapy on intracerebral leukemia 1210.
    Caron N, Lee SH, Kimball AP.
    Cancer Res; 1977 Sep 15; 37(9):3274-9. PubMed ID: 884674
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Basis of observed resistance of L1210 leukemia in mice: methotrexate, 6-thioguanine, 6-methylmercaptopurine riboside, 6-mercaptopurine, 5-fluorouracil, and 1-beta-D-arabinofuranosylcytosine administered in different combinations.
    Kim K, Blechman WJ, Riddle VG, Pardee AB.
    Cancer Res; 1981 Nov 15; 41(11 Pt 1):4529-34. PubMed ID: 7198006
    [Abstract] [Full Text] [Related]

  • 16. Immunosuppressive activity of methotrexate and arabinosyl cytosine in mice bearing L1210 leukaemia.
    Baldini L, Brambilla G, Cavanna M, Parodi S.
    Br J Pharmacol; 1968 Nov 15; 34(3):674P-676P. PubMed ID: 5726804
    [No Abstract] [Full Text] [Related]

  • 17. Schedule-dependent synergism for the combination of 1-beta-D-arabinofuranosylcytosine and daunorubicin.
    Edelstein M, Vietti T, Valeriote F.
    Cancer Res; 1974 Feb 15; 34(2):293-7. PubMed ID: 4810905
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Biochemical and antitumor effects of the combination of thymidine and 1-beta-D-arabinofuranosylcytosine against leukemia L1210.
    Kinahan JJ, Kowal EP, Grindey GB.
    Cancer Res; 1981 Feb 15; 41(2):445-51. PubMed ID: 7448789
    [No Abstract] [Full Text] [Related]

  • 20. Pharmacokinetics and cellular determinants of response to 1-beta-arabinofuranosylcytosine (ara-C).
    Riva CM, Rustum YM, Preisler HD.
    Semin Oncol; 1985 Jun 15; 12(2 Suppl 3):1-8. PubMed ID: 3859925
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.